Selvita S.A. - Asset Resilience Ratio
Selvita S.A. (SLV) has an Asset Resilience Ratio of 0.06% as of June 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read SLV total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2023)
This chart shows how Selvita S.A.'s Asset Resilience Ratio has changed over time. See what is Selvita S.A.'s book value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Selvita S.A.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Selvita S.A. stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | zł0.00 | 0% |
| Short-term Investments | zł367.00K | 0.06% |
| Total Liquid Assets | zł367.00K | 0.06% |
Asset Resilience Insights
- Limited Liquidity: Selvita S.A. maintains only 0.06% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Selvita S.A. Industry Peers by Asset Resilience Ratio
Compare Selvita S.A.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Eurofins-Cerep SA
PA:ALECR |
Diagnostics & Research | 6.56% |
|
Inoviq Ltd
AU:IIQ |
Diagnostics & Research | 56.29% |
|
Bcal Diagnostics Ltd
AU:BDX |
Diagnostics & Research | 0.00% |
|
Imagion Biosystems Ltd
AU:IBX |
Diagnostics & Research | 150.16% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
Annual Asset Resilience Ratio for Selvita S.A. (2016–2023)
The table below shows the annual Asset Resilience Ratio data for Selvita S.A..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.05% | zł311.00K ≈ $85.59K |
zł636.26 Million ≈ $175.11 Million |
-0.30pp |
| 2022-12-31 | 0.35% | zł2.02 Million ≈ $555.38K |
zł584.91 Million ≈ $160.98 Million |
-2.53pp |
| 2021-12-31 | 2.88% | zł13.43 Million ≈ $3.70 Million |
zł466.59 Million ≈ $128.41 Million |
-1.76pp |
| 2020-12-31 | 4.64% | zł10.15 Million ≈ $2.79 Million |
zł218.80 Million ≈ $60.22 Million |
+4.52pp |
| 2018-12-31 | 0.12% | zł89.37K ≈ $24.60K |
zł72.58 Million ≈ $19.98 Million |
-0.07pp |
| 2017-12-31 | 0.19% | zł92.69K ≈ $25.51K |
zł47.94 Million ≈ $13.19 Million |
+0.13pp |
| 2016-12-31 | 0.07% | zł60.00K ≈ $16.51K |
zł89.12 Million ≈ $24.53 Million |
-- |
About Selvita S.A.
Selvita S.A. operates as a contract research organization worldwide. The company offers drug discovery services in the areas of AI-driven drug discovery, antibody drug discovery, structural biology, recombinant protein production, assay development and screening, computer-aided drug design, medicinal and synthetic chemistry, scale-up, ADME/DMPK, in vitro and In Vivo pharmacology, translational re… Read more